The Developing Life Sciences Industries of China and India

Countries covered: China, India The drive by multinational pharmaceutical companies (MPCs) to gain access to emerging markets and their willingness to outsource key R&D activities is fueling the growth of a domestic life sciences marketplace in both China and India. Growth in this sector is in turn promoting innovative drug development, both by local pharmaceutical companies and by emerging biotechnology firms. As this industry sector develops, many local players will turn to MPCs for support through partnerships and collaboration. Questions Answered India and China are key targets for pharmaceutical companies to access emerging markets and to reduce the cost of R&D. What features of China and India make them attractive targets for these strategies? How are pharmaceutical companies engaging local markets to accomplish their goals? Which strategies are likely to be most successful? China and India have both developed poor reputations for protecting intellectual property (IP), but the IP landscape is improving. What changes have China and India made to improve their protection of IP? What examples demonstrate the existing challenges to drug developers trying to protect IP in India and China? What is the impact of IP policies on investment in these countries? Chinese and Indian governments are both supporting the development of their local biotech industries. What measures have governments taken to provide support to the life sciences? What vehicles are used to provide this support? Several business models predominate the Chinese and Indian life sciences sectors. How are life sciences companies structured in China and India? How are these business models evolving? Which companies fare applying these different models? The availability of private capital and access to public markets is important for the development of the biotech industry. What is the state of venture capital financing in China and India? How are governments supporting venture capital funding of biotech companies? What is the environment like for foreign investors? Most Western pharmaceutical companies have made major investments in the Chinese and Indian pharmaceutical and life sciences market. What types of investments are pharmaceutical companies making in each country? Who are the major players? What significant dealmaking activities are taking place? Scope Economic development: Economic growth, GDP growth, position in global economy, pharmaceutical market growth, life sciences growth Business infrastructure: Intellectual property protection and challenges, strengths in sciences, government sources of funding and support Evolving life sciences business model: Generics drug companies, contract research organizations, biotechnology companies, combination models Pharmaceutical investment: Offshoring facilities, joint ventures, corporate partnerships, collaborations, M&As Outlook: Returnees, academic collaborations, financial constraints, infrastructure Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies Mentioned

- Abbott Laboratories

- Accutest India

- Advinus

- Allist Pharmaceuticals

- Ashco Niulab

- AstraZeneca

- Aurigene Discovery Technologies

- Aurobindo Pharma

- AutekBio

- Avesthagen

- Avra Laboratories

- Bangalore Genei

- Bayer HealthCare

- Beike Biotechnology

- Beta Pharma

- BGI

- Bharat Biotech

- Bicoll Biotechnology

- Biocon

- Biological E

- Beijing Skywing Technology

- Boehringer Ingelheim

- BrightGene

- Bristol-Myers Squibb

- Cadila Pharmaceuticals

- Charles River Laboratories

- China Pharmaceutical Group

- Chinese National Human Genome Center

- Chipscreen Biosciences

- Cipla

- CITIC Pharmaceuticals

- Claris Lifesciences

- Clintox Bioservices

- Dr Reddy’s Laboratories

- Eli Lily

- GlaxoSmithKline

- Glenmark Pharmaceuticals

- Guanghzhou

- GVK Bio

- HD Biosciences

- Hutchison MediPharma

- Indian Institute of Chemical Technology

- Institute for Toxicological Studies (Intox)

- Jubilant Life Sciences

- Lupin Pharmaceuticals

- Merck

- Merck KGaA

- Mindray Medical International

- Nanjing MeiRui Pharmaceuticals

- Nicholas Piamal India

- North China Pharmaceutical

- Novavax

- Novartis

- Novast

- Piramal Life Sciences

- Pfizer

- Piramal Healthcare

- Ranbaxy Laboratories

- RCC Laboratories

- Reliance Biosciences

- Reliance Clinical Research Services

- Roche

- Sai Advantium

- Sanjiu Medical & Pharmaceutical

- Sanofi

- Shantha Biotechnics

- Suven Life Sciences

- Syngene

- Shanghai Medicilon

- Shanghai Newsummit Biopharma

- Shanghai Ambrosia Pharmaceutical

- Shanghai ChemExplorer

- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

- Shanghai Institute of Materia Medica, Chinese Academy of Sciences

- Shenzhen Accord Pharmaceutical

- Simcere Pharmaceutical

- Sinopharm Group

- Sun Pharma

- Sundia MediTech

- TATA Group

- United Laboratories International

- VaxInnate

- WuXi PharmaTech

- Yunnan Baiyo Group

- Zydus Cadila

- Zhejiang Huahai Pharmaceutical

- Zhejiang Tianyuan Bio-Pharmaceutical

More India Manufacturing, Packaging & Detailing Reports

Oncology Pharmaceuticals Market in India 2012 by Netscribes (India) Pvt. Ltd.
Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in ...

Cardiovascular Pharmaceuticals Market in India 2012 by Netscribes (India) Pvt. Ltd.
Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the ...

Anti-Infective Pharmaceuticals Market in India 2012 by Netscribes (India) Pvt. Ltd.
Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian ...

India Pharmaceutical Industry Research and Forecast to 2016 by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “India Pharmaceutical Industry Research and Forecast to 2016” offer detailed analysis on the country’s bulk and formulations market which is sub-segmented ...

Anti-Diabetic Pharmaceuticals Market in India 2012 by Netscribes (India) Pvt. Ltd.
Anti-diabetic pharmaceuticals market in India is one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in ...

See all reports like this >>

More India Reports

D&B Country RiskLine Report: India by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: India by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report India January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

India: Country Profile by MarketLine
INTRODUCTION This report provides a detailed analysis on India, providing an overview of its political, economic and business environment, represented both textually and in graph and ...

2007 India Industry & Market Outlook report by Barnes Reports
The 2007 India Industry & Market Outlook report is the leading annual publication that describes over 100 major industries in India and 500+ minor industries ...

See all reports like this >>